Zydus Cadila received final approval from the US Food Drug Administration to sell new generation anti-depressant Vortioxetine in the strengths of 5 mg, 10 mg, 20 mg in US market.
The drug was first approved around seven years ago, and was developed by Denmark-based pharmaceuticals maker Lundbeck in the late 2000s.
Vortioxetine works by increasing serotonin in the brain by preventing the elimination and reuptake of seratonin in the brain, and is classified as a selective serotonin reuptake inhibitor and serotonin receptor modulator.
